Table 3.

Baseline demographic and clinical characteristics of included participants.

Subject	Age (years)	Sex	Duration of disease (years)	L-Dopa dose (mg)	Education (years)
1	72	Male	2	800	16
2	64	Female	2	450	5
3	73	Male	1	200	13
4	79	Male	10	300	5
5	80	Female	3	300	13
6	69	Male	9	750	8
7	61	Female	11	600	11
8	75	Male	18	600	13
9	71	Male	6	400	17
10	63	Male	7	450	10
11	68	Male	2	300	17
12	60	Male	2	200	17
13	65	Female	8	400	5
14	66	Female	6	600	17
15	83	Female	4	400	5